杨靖,李毅,裘淼涵,王贺阳,徐凯,荆全民,韩雅玲,李晶

• 1:沈阳军区总医院心内科

摘要(Abstract)：

目的比较老年患者置入新型药物洗脱支架(BP-SES)术后,应用6个月与12个月双联抗血小板治疗(DAPT)的疗效和安全性。方法纳入I-LOVE-IT 2研究中置入BP-SES老年患者(≥65岁)627例,其中接受6个月DAPT治疗319例(6个月DAPT组),12个月DAPT治疗308例(12个月DAPT组)。本研究的主要终点为12个月的靶病变失败(TLF,包含心源性死亡、靶血管心肌梗死和临床驱动的靶病变再次血运重建的复合终点),次要终点为12个月净不良临床事件(NACE,包含全因死亡、心肌梗死、缺血性卒中或全部出血的复合终点)以及12个月支架内血栓形成发生率。结果两组患者年龄、性别、体重指数、糖尿病、高血压病等方面比较,差异均无统计学意义(均P>0.05)。基线SYNTAX评分、靶病变个数、靶血管位置等基线造影特征方面比较,差异均无统计学意义(均P>0.05)。随访12个月Kaplan-Meier累积事件,6个月DAPT组主要终点TLF发生率(7.2%比7.1%,P=0.980),次要终点NACE发生率(14.1%比13.0%,P=0.726),支架内血栓形成发生率(2.8%比1.0%,P=0.101)与12个月DAPT组比较,差异均无统计学意义。明确或极可能的支架内血栓形成共5例,其中6个月和12个月DAPT组分别有3例和2例(0.9%比0.6%,P=0.682),差异无统计学意义。界标分析结果显示,在6至12个月随访期间,6个月DAPT组TLF(2.3%比1.7%,P=0.593),NACE事件发生率(4.2%比2.9%,P=0.392),出血发生率(1.0%比1.0%,P=0.961)与12个月DAPT组比较,差异无统计学意义。结论在接受新一代药物洗脱支架置入的老年患者中,术后接受6个月DAPT治疗者,有效性和安全性与接受12个月DAPT的患者差异无统计学意义。

关键词(KeyWords)： 老年;双联抗血小板治疗;聚合物涂层可降解西罗莫司(雷帕霉素)药物洗脱支架

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 杨靖,李毅,裘淼涵,王贺阳,徐凯,荆全民,韩雅玲,李晶

参考文献(References)：

• [1]Andreotti F,Rocca B,Husted S,et al.Antithrombotic therapy in the elderly:expert position paper of the European Society of Cardiology Working Group on Thrombosis.Eur Heart J,2015,36(46):3238-3249
• [2]Galasso G,De Servi S,Savonitto S,et al.Eff ect of an invasive strategy on outcome in patients≥75 years of age with non-STelevation acute coronary syndrome.Am J Cardiol,2015,115(5):576-580.
• [3]Roth GA,Forouzanfar MH,Moran AE,et al.Demographic and epidemiologic drivers of global cardiovascular mortality.N Engl J Med,2015,372(14):1333-1341.
• [4]Hamm CW,Bassand JP,Agewall S,et al.ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:The Task Force for the management of acute coronary syndromes(ACS)in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC).Eur Heart J,2011,32(23):2999-3054.
• [5]Windecker S,Kolh P,Alfonso F,et al.2014 ESC/EACTS Guidelines on myocardial revascularization:The Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC)and the European Association for Cardio-Thoracic Surgery(EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI).Eur Heart J,2014,35(37):2541-2619.
• [6]Levine GN,Bates ER,Bittl JA,et al.2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease:A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.J Thorac Cardiovasc Surg,2016,152(5):1243-1275.
• [7]Briasoulis A,Palla M.Duration of dual antiplatelet therapy after coronary stenting.Int J Cardiol,2016,222:1064-1067.
• [8]Piccolo R,Windecker S.Dual Antiplatelet Therapy in Percutaneous Coronary Intervention:A Tale of 2 Decades With New Perspectives in the Era of New-Generation Drug-Eluting Stents.Circ Cardiovasc Interv,2016,9(2).[Epub ahead of print]
• [9]Ben-Dor I,Torguson R,Scheinowitz M,et al.Incidence,correlates,and clinical impact of nuisance bleeding af ter antiplatelet therapy for patients with drug-eluting stents.Am Heart J,2010,159(5):871-875.
• [10]Calmac L,B?t?il?V,Ricci B,et al.Factors associated with use of percutaneous coronary intervention among elderly patients presenting with ST segment elevation acute myocardial infarction(STEMI):Results from the ISACS-TC registry.Int J Cardiol,2016,217 Suppl:S21-S26.
• [11]Han Y,Xu B,Jing Q,et al.A randomized comparison of novel biodegradable polymer-and durable polymer-coated cobaltchromium sirolimus-eluting stents.JACC Cardiovasc Interv,2014,7(12):1352-1360.
• [12]Mehran R,Rao SV,Bhatt DL,et al.Standardized bleeding defi nitions for cardiovascular clinical trials:a consensus report from the Bleeding Academic Research Consortium.Circulation,2011,123(23):2736-2747.
• [13]Pfi sterer M,Brunner-La Rocca HP,Buser PT,et al.Late clinical events after clopidogrel discontinuation may limit the benefi t of drug-eluting stents:an observational study of drugeluting versus bare-metal stents.J Am Coll Cardiol,2006,48(12):2584-2591.
• [14]Mauri L,Kereiakes DJ,Yeh RW,et al.Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.N Engl J Med,2014,371(23):2155-2166.
• [15]Navarese EP,Andreotti F,Schulze V,et al.Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents:meta-analysis of randomised controlled trials.BMJ,2015,350:h1618.
• [16]Palmerini T,Benedetto U,Bacchi-Reggiani L,et al.Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation:a pairwise and Bayesian network meta-analysis of randomised trials.Lancet,2015,385(9985):2371-2382.
• [17]Han Y,Jing Q,Xu B,et al.Safety and effi cacy of biodegradable polymer-coated sirolimus-eluting stents in“real-world”practice:18-month clinical and 9-month angiographic outcomes.JACC Cardiovasc Interv,2009,2(4):303-309.
• [18]Colombo A,Chieff o A,Frasheri A,et al.Second-generation drug-eluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy:the SECURITY randomized clinical trial.J Am Coll Cardiol,2014,64(20):2086-2097.
• [19]Gilard M,Barragan P,Noryani AAL,et al.6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin:the randomized,multicenter ITALIC trial.J Am Coll Cardiol,2015,65(8):777-786.
• [20]Piccolo R,Magnani G,Ariotti S,et al.Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention:insights from the PRODIGY randomised trial.Euro Intervention,2017,13(1):78-86.
• [21]Numasawa Y,Kohsaka S,Ueda I,et al.Incidence and predictors of bleeding complications after percutaneous coronary intervention.J Cardiol,2017,69(1):272-279.
• [22]Li L,Geraghty OC,Mehta Z,et al.Age-specifi c risks,severity,time course,and outcome of bleeding on long-term antiplatelet treatment after vascular events:a population-based cohort study.Lancet,2017,390(10093):490-499.
• [23]Amin AP,Wang TY,Mc Coy L,et al.Impact of Bleeding on Quality of Life in Patients on DAPT:Insights From TRANSLATE-ACS.J Am Coll Cardiol,2016,67(1):59-65.
• [24]王江友,苏晞.冠状动脉支架置入后双联抗血小板治疗时限的研究和临床决策.中国介入心脏病学杂志,2016,24(3):160-165.
• [25]韩雅玲.《2016年美国心脏病学会/美国心脏协会冠心病患者双联抗血小板治疗疗程指南更新》解读.中国介入心脏病学杂志,2016,24(11):603-606.